Murray, J, Pratt, G, Jacob, A, Clark, F, Blundred, R, Fox, S, Bishop, R, Wheatley, K, Khanim, F, Bunce, C and Drayson, M (2019) Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers. Contemporary Clinical Trials Communications, 14. 100361 - ?. ISSN 2451-8654

[thumbnail of R Blundred - Single arm phase II trial assessing the safety....pdf]
R Blundred - Single arm phase II trial assessing the safety....pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (182kB) | Preview


We previously reported the safety and efficacy of low dose BaP [Bezafibrate (Bez) and Medroxyprogesterone acetate (MPA)] in 20 acute myeloid leukaemia (AML) patients for whom chemotherapy was not an option. This study provided evidence that BaP had anti-AML activity and improved haemopoiesis; absence of haematological toxicity allowed continuous daily administration. Similarly a previous trial in endemic Burkitt lymphoma demonstrated anti-B cell lymphoma activity of low and high dose BaP again in the absence of toxicity. We conducted a study to further evaluate the safety and activity of high dose BaP therapy in adults with AML (and high risk Myelodysplastic Syndromes (MDS)), chronic lymphocytic leukaemia (CLL) or B-cell Non-Hodgkin Lymphoma (BHNL). Eighteen patients were recruited to the study over 20 months, 16 AML/MDS, 1 CLL, and 1 BNHL. Although MPA was well tolerated throughout the study, only 2 patients were able to tolerate Bez treatment for their whole trial duration, indicating that Bez escalation is not feasible in the setting of adult AML/MDS. Thus there has been no obvious benefit in improved haemopoiesis or overt anti-leukaemia activity from the attempts to escalate BaP dose over previous published studies. Since current therapeutic options in MDS are restricted it may be now of value to continue to evaluate low dose BaP based approaches in low risk MDS rather than AML/high risk MDS. Furthermore, screening of low dose BaP against libraries of other already available dugs may identify an addition to BaP that augments the anti-neoplastic efficacy without significant toxicity.

Item Type: Article
Uncontrolled Keywords: Clinical trials; Myeloid leukaemia; Lymphoid malignancies; Therapy; Bezafibrate; Progesterone
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Natural Sciences > School of Life Sciences
Related URLs:
Depositing User: Symplectic
Date Deposited: 30 Apr 2019 08:45
Last Modified: 30 Apr 2019 08:45

Actions (login required)

View Item
View Item